MX2019007067A - Inhibidores de azepano de la interacción menina-mll. - Google Patents

Inhibidores de azepano de la interacción menina-mll.

Info

Publication number
MX2019007067A
MX2019007067A MX2019007067A MX2019007067A MX2019007067A MX 2019007067 A MX2019007067 A MX 2019007067A MX 2019007067 A MX2019007067 A MX 2019007067A MX 2019007067 A MX2019007067 A MX 2019007067A MX 2019007067 A MX2019007067 A MX 2019007067A
Authority
MX
Mexico
Prior art keywords
menin
azepane
inhibitors
mll interaction
compounds
Prior art date
Application number
MX2019007067A
Other languages
English (en)
Inventor
René Angibaud Patrick
Noëlle Constance Pilatte Isabelle
Alexis Georges Querolle Olivier
Pande Vineet
Herkert Barbara
Jason Krosky Daniel
Nathaniel Patrick Aaron
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2017/082826 external-priority patent/WO2018109088A1/en
Publication of MX2019007067A publication Critical patent/MX2019007067A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se relaciona con agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero y, en particular, con compuestos de azepam, la composición farmacéutica que comprende tales compuestos, y su uso como inhibidores de la interacción menina/MLL proteína/proteína, útiles para tratar enfermedades tales como cáncer, síndrome mielodisplástico (MDS, pos sus siglas en inglés) y diabetes.(ver formula).
MX2019007067A 2016-12-15 2017-12-14 Inhibidores de azepano de la interacción menina-mll. MX2019007067A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434549P 2016-12-15 2016-12-15
EP17150502 2017-01-06
PCT/EP2017/082826 WO2018109088A1 (en) 2016-12-15 2017-12-14 Azepane inhibitors of menin-mll interaction

Publications (1)

Publication Number Publication Date
MX2019007067A true MX2019007067A (es) 2019-10-15

Family

ID=60935807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007067A MX2019007067A (es) 2016-12-15 2017-12-14 Inhibidores de azepano de la interacción menina-mll.

Country Status (11)

Country Link
US (2) US10745409B2 (es)
EP (1) EP3555103B1 (es)
JP (1) JP7142010B2 (es)
KR (1) KR102513564B1 (es)
CN (1) CN110248946B (es)
AU (1) AU2017376599B2 (es)
BR (1) BR112019012106A2 (es)
CA (1) CA3044739A1 (es)
ES (1) ES2901227T3 (es)
IL (1) IL267277B (es)
MX (1) MX2019007067A (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
AU2003223237C1 (en) 2002-02-19 2009-03-26 Gilead Palo Alto, Inc. Partial and full agonists of A1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US20040138238A1 (en) * 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
ES2282731T3 (es) 2002-12-23 2007-10-16 Janssen Pharmaceutica N.V. Derivados de 1-piperidin-4-il-4-azetidin-3-il-piperazina sustituida y su uso como antagonistas de neuroquininas.
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
JP4545196B2 (ja) 2005-01-19 2010-09-15 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
WO2010041366A1 (ja) 2008-10-06 2010-04-15 日本電気株式会社 無線通信装置、無線通信システム、無線通信装置の制御方法、及び記録媒体
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
AU2010289321A1 (en) * 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
CA2819620A1 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
KR20130124959A (ko) 2010-12-03 2013-11-15 에피자임, 인코포레이티드 히스톤 메틸전달효소의 7-데아자퓨린 조절제 및 그의 사용방법
EP2620094B1 (en) 2011-08-01 2015-10-14 Olympus Corporation Apparatus for displaying shape of insertion portion
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
PT2935222T (pt) 2012-12-21 2018-12-10 Epizyme Inc Inibidores de prmt5 e seus usos
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
CN105188705A (zh) 2013-03-13 2015-12-23 密歇根大学董事会 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法
WO2015191701A1 (en) * 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US10526341B2 (en) 2014-11-19 2020-01-07 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CU20170105A7 (es) 2015-02-24 2017-10-05 Pfizer Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
EP3394064A1 (en) 2015-12-22 2018-10-31 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
JP7000333B2 (ja) 2016-03-16 2022-02-10 クラ オンコロジー，インク． メニン－ｍｌｌの架橋された二環式阻害剤及びその使用方法
HRP20230537T1 (hr) 2016-03-16 2023-08-04 Kura Oncology, Inc. Supstituirani derivati tieno[2,3-d]pirimidina kao inhibitori za menin-mll i postupci za uporabu
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
JP7071644B2 (ja) 2016-09-06 2022-05-19 株式会社スリーボンド 熱硬化型導電性接着剤
DK3512857T3 (da) 2016-09-14 2021-05-10 Janssen Pharmaceutica Nv Spiro-bicykliske inhibitorer af menin-mll-interaktion
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
AU2017326485B2 (en) 2016-09-14 2021-04-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-MLL interaction
MX2019003091A (es) 2016-09-16 2019-07-08 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-mll.
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
EP3601249A4 (en) 2017-03-24 2020-12-16 Kura Oncology, Inc. METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA

Also Published As

Publication number Publication date
EP3555103A1 (en) 2019-10-23
KR102513564B1 (ko) 2023-03-22
IL267277A (en) 2019-08-29
CA3044739A1 (en) 2018-06-21
US11530226B2 (en) 2022-12-20
CN110248946B (zh) 2023-05-23
KR20190092518A (ko) 2019-08-07
CN110248946A (zh) 2019-09-17
US20190322685A1 (en) 2019-10-24
ES2901227T3 (es) 2022-03-21
AU2017376599A1 (en) 2019-08-01
US20200339594A1 (en) 2020-10-29
IL267277B (en) 2022-04-01
EP3555103B1 (en) 2021-09-22
BR112019012106A2 (pt) 2019-10-29
AU2017376599B2 (en) 2021-10-07
JP7142010B2 (ja) 2022-09-26
JP2020512290A (ja) 2020-04-23
US10745409B2 (en) 2020-08-18

Similar Documents

Publication Publication Date Title
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
EA201991448A1 (ru) Азепановые ингибиторы взаимодействия менин-mll
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
NZ719905A (en) Bicyclic heterocycle compounds and their uses in therapy
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
EA201791933A1 (ru) Ингибирование активности olig2
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
MX2017009608A (es) Compuestos anticancerigenos.
MX2019007067A (es) Inhibidores de azepano de la interacción menina-mll.
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
EA201990700A1 (ru) Конденсированные бициклические ингибиторы взаимодействия менин–mll
EA033077B1 (ru) Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение
BR112015024571A2 (pt) compostos de complexo de ferro(iii), medicamento, e, composição